Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics.
In order to prevent the increasing frequency of per-operative infections, bioceramics can be loaded with anti-bacterial agents, which will release with respect to their chemical characteristics. A novel hydroxyapatite (HA) was elaborated with specific internal porosities for using as a bone-bioactive antibiotic (ATB) carrier material. UV spectrophotometry and bacteria inhibition tests were performed for testing the ATB adsorption and the microbiological effectiveness after loading with different antibiotics. The impregnation time, ATB impregnating concentration, impregnation condition and other factors, which might influence the ATB loading effect, were studied by exposure to different releasing solvents and different pathogenic bacteria: Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli. It clearly showed that the facility of ATB loading on this porous HA is even possible just under simple non-vacuum impregnation conditions in a not-so-long impregnating interval. The results also showed that, for all three types of ATB (vancomycin, ciprofloxacin and gentamicin), adsorbed amount on the micro-porous HA were hugely higher than that on dense HA. The micro-porosity of test HA had also significantly prolonged the release time of antibiotics even under mimic physiological conditions. Furthermore, it also has primarily proved by a pilot test that the antibacterial efficiency of crude micro-porous HA could be further significantly improved by other methods of functionalization such as cold plasma technique.
Chai
F
F
Groupe de Recherche sur les Biomatériaux, EA 1049, Faculté de Médecine, 59045 Lille, France.
Hornez
J-C
JC
Blanchemain
N
N
Neut
C
C
Descamps
M
M
Hildebrand
H F
HF
D000327:Adsorption; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000737:chemistry / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000737:chemistry / Q000494:pharmacology; D017886:Durapatite / Q000737:chemistry / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects*; D005839:Gentamicins / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D010316:Particle Size; D010865:Pilot Projects; D016062:Porosity; D013211:Staphylococcus aureus / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*; D013499:Surface Properties; D014640:Vancomycin / Q000737:chemistry / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D005839:Gentamicins; D002939:Ciprofloxacin; D014640:Vancomycin; D017886:Durapatite